Find policies, billing codes, payers, states, and providers

CPT 0547U: Neurofilament Light Plasma Quantitative Assay

CPT code 0547U denotes a Proprietary Laboratory Analyses (PLA) test for measuring neurofilament light chain (NfL) in plasma using a chemiluminescent enzyme immunoassay. As a PLA code, 0547U is tied to a single test produced by specific manufacturers (Neurocode USA Inc. and Fujirebio Diagnostics Inc.), and it standardizes reporting for quantitative NfL results. Nationally, NfL testing has growing clinical relevance as a blood-based biomarker for neuronal injury and neurodegeneration, influencing diagnostic pathways and monitoring strategies across neurology practices.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides readers with an overview of coverage and billing considerations for 0547U, typical sites of service, and the clinical context for ordering plasma NfL testing. Readers will find benchmarks and policy-relevant summaries where available, clinical background on the assay and its intended use, and practical billing metadata such as common modifier usage. Data not provided in the input (including specific coverage policies, reimbursement rates, associated taxonomies, ICD-10 mappings, and related codes) are noted as not available in the input.

Customize your policy alerts

Sign up for cpt 0547U policy alerts

Get alerted when payer policies referencing 0547U are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

CPT code 0547U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to a single laboratory test: the Neurofilament Light Blood Test offered by Neurocode USA Inc. and Fujirebio Diagnostics Inc. The test quantitatively measures neurofilament light chain (NfL) concentration in plasma using a chemiluminescent enzyme immunoassay technique. Results are reported as numeric values reflecting NfL levels, used as a biomarker in neurological assessment.

Service Type: Proprietary laboratory blood test (plasma NfL quantification)

Typical Site of Service: Clinical laboratory or reference diagnostic laboratory; specimen collection in outpatient clinics or phlebotomy centers.

Explore openpayer tools

View all tools

Find policies, billing codes, payers, states, and providers

CPT 0547U: Neurofilament Light Plasma Quantitative Assay

Customize your policy alerts

Sign up for cpt 0547U policy alerts

Get alerted when payer policies referencing 0547U are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Service Type: Proprietary laboratory blood test (plasma NfL quantification)

Typical Site of Service: Clinical laboratory or reference diagnostic laboratory; specimen collection in outpatient clinics or phlebotomy centers.

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with progressive cognitive decline and gait instability is seen in a neurology clinic for evaluation of suspected neurodegenerative disease. The clinician orders a plasma neurofilament light chain (NfL) assay performed by Neurocode USA Inc. or Fujirebio Diagnostics Inc. using a chemiluminescent enzyme immunoassay to obtain a quantitative NfL concentration. A phlebotomy is scheduled at an outpatient laboratory or hospital outpatient phlebotomy center; the specimen is sent to the proprietary laboratory performing 0547U. Results are reported quantitatively and interpreted by the ordering neurologist in the context of clinical exam, neuroimaging, and other biomarkers. Typical sites of service include hospital outpatient departments, independent clinical laboratories, and outpatient specialty clinics with specimen collection capability. This test is used to aid in assessment of neuronal injury, disease activity monitoring, and to support differential diagnosis among neurodegenerative, inflammatory, and traumatic neurologic conditions.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard reporting	Use when submitting the single, primary PLA code without service variations.
`22`	Increased procedural services	Use when work required to obtain, process, or interpret the specimen is substantially greater than typical.
`52`	Reduced services	Use when the test is partially reduced or not fully performed.
`53`	Discontinued procedure	Use if specimen collection or testing was started but halted for clinical reasons.

Taxonomy Code	Specialty	Notes
`2084P0800X`	Neurology	Ordering providers who interpret NfL results and manage neurodegenerative disease.
`207L00000X`	Clinical Pathology	Laboratories that perform and oversee neurochemical assays.
`208000000X`	Neuromuscular Medicine	Specialists using NfL for peripheral and central nervous system injury assessment.
`2086S0122X`	Behavioral Neurology & Neuropsychiatry	Clinicians using biomarkers in cognitive disorder evaluation.
`363L00000X`	Independent Laboratory	Facilities that may perform or send out PLA tests.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G31.9`	Neurodegenerative disease, unspecified	NfL may be used to assess neuronal injury in suspected neurodegenerative disorders.
`G20`	Parkinson's disease	NfL can help in monitoring neurodegeneration and disease progression.
`F02.80`	Dementia in other diseases classified elsewhere without behavioral disturbance	NfL levels assist in differentiating neurodegenerative causes of dementia.
`G35`	Multiple sclerosis	NfL is a biomarker of neuronal damage and disease activity monitoring in MS.
`S06.5X9A`	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, initial encounter	NfL can reflect acute axonal injury after traumatic brain injury.
`G61.9`	Inflammatory polyneuropathy, unspecified	NfL may be elevated in peripheral nervous system axonal injury and inflammatory neuropathies.
`R41.3`	Other amnesia	NfL may be included in evaluation of patients with cognitive symptoms including amnesia.
`R47.01`	Aphasia	Use in assessment of underlying neurodegenerative or vascular processes when combined with clinical evaluation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Venipuncture is the typical specimen collection method prior to sending plasma for `0547U`.
`0034U`	(Example PLA molecular or biomarker assay)	Laboratories may perform additional biomarker PLAs alongside `0547U` for comprehensive neurodegenerative workup.
`81025`	Urine pregnancy test, non-automated, qualitative (for female patients of reproductive potential)	Often performed prior to certain imaging or treatments linked to diagnostic workup but not specific to `0547U`.
`80500`	Therapeutic drug assay (qualitative or semi-quantitative), multiple drugs	Other laboratory tests that may be ordered concurrently in a neurologic diagnostic panel.
`80053`	Comprehensive metabolic panel	Commonly ordered adjunct labs to evaluate systemic contributors when assessing neurologic disease.

CPT 0001U: PreciseType HEA Multiplex Erythrocyte Antigen Assay

CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

CPT 0002U: Urine Metabolomic Polyp Risk Assay (PolypDX™)

CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

CPT 0003U: Overa™ (OVA1 Next Generation) Ovarian Cancer Risk Assay

CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

CPT 0005U: ExosomeDx Prostate (IntelliScore) Urine Gene Expression Risk Test

CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

CPT 0007U: ToxProtect Urine Drug Screen with DNA Authentication

CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

CPT 0008U: H. pylori Antibiotic Resistance Panel, Gene Sequence Analysis

CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

CPT 0011U: Cordant CORE™ Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcript Testing

Showing 1–10 of 536

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard reporting	Use when submitting the single, primary PLA code without service variations.
`22`	Increased procedural services	Use when work required to obtain, process, or interpret the specimen is substantially greater than typical.
`52`	Reduced services	Use when the test is partially reduced or not fully performed.
`53`	Discontinued procedure	Use if specimen collection or testing was started but halted for clinical reasons.

Taxonomy Code	Specialty	Notes
`2084P0800X`	Neurology	Ordering providers who interpret NfL results and manage neurodegenerative disease.
`207L00000X`	Clinical Pathology	Laboratories that perform and oversee neurochemical assays.
`208000000X`	Neuromuscular Medicine	Specialists using NfL for peripheral and central nervous system injury assessment.
`2086S0122X`	Behavioral Neurology & Neuropsychiatry	Clinicians using biomarkers in cognitive disorder evaluation.
`363L00000X`	Independent Laboratory	Facilities that may perform or send out PLA tests.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G31.9`	Neurodegenerative disease, unspecified	NfL may be used to assess neuronal injury in suspected neurodegenerative disorders.
`G20`	Parkinson's disease	NfL can help in monitoring neurodegeneration and disease progression.
`F02.80`	Dementia in other diseases classified elsewhere without behavioral disturbance	NfL levels assist in differentiating neurodegenerative causes of dementia.
`G35`	Multiple sclerosis	NfL is a biomarker of neuronal damage and disease activity monitoring in MS.
`S06.5X9A`	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, initial encounter	NfL can reflect acute axonal injury after traumatic brain injury.
`G61.9`	Inflammatory polyneuropathy, unspecified	NfL may be elevated in peripheral nervous system axonal injury and inflammatory neuropathies.
`R41.3`	Other amnesia	NfL may be included in evaluation of patients with cognitive symptoms including amnesia.
`R47.01`	Aphasia	Use in assessment of underlying neurodegenerative or vascular processes when combined with clinical evaluation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Venipuncture is the typical specimen collection method prior to sending plasma for `0547U`.
`0034U`	(Example PLA molecular or biomarker assay)	Laboratories may perform additional biomarker PLAs alongside `0547U` for comprehensive neurodegenerative workup.
`81025`	Urine pregnancy test, non-automated, qualitative (for female patients of reproductive potential)	Often performed prior to certain imaging or treatments linked to diagnostic workup but not specific to `0547U`.
`80500`	Therapeutic drug assay (qualitative or semi-quantitative), multiple drugs	Other laboratory tests that may be ordered concurrently in a neurologic diagnostic panel.
`80053`	Comprehensive metabolic panel	Commonly ordered adjunct labs to evaluate systemic contributors when assessing neurologic disease.

CPT 0001U: PreciseType HEA Multiplex Erythrocyte Antigen Assay

CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

CPT 0002U: Urine Metabolomic Polyp Risk Assay (PolypDX™)

CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

CPT 0003U: Overa™ (OVA1 Next Generation) Ovarian Cancer Risk Assay

CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

CPT 0005U: ExosomeDx Prostate (IntelliScore) Urine Gene Expression Risk Test

CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

CPT 0007U: ToxProtect Urine Drug Screen with DNA Authentication

CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

CPT 0008U: H. pylori Antibiotic Resistance Panel, Gene Sequence Analysis

CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

CPT 0011U: Cordant CORE™ Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcript Testing

Showing 1–10 of 536

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

CPT 0547U: Neurofilament Light Plasma Quantitative Assay

Sign up for cpt 0547U policy alerts

Billing Code Overview

OpenPayer

CPT 0547U: Neurofilament Light Plasma Quantitative Assay

Sign up for cpt 0547U policy alerts

Billing Code Overview

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

References

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

References